Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reimbursed repeat volume.
References
Sources used in this report
SEC submissionsSEC submissions API for Aclarion, Inc.2026-05-13 · Issuer identity, CIK, SIC, exchange, fiscal year, listed securities, and recent filing set.SEC XBRL companyfactsSEC companyfacts API for Aclarion, Inc.2026-05-13 · Official XBRL cross-check for revenue, cash, assets, liabilities, equity, operating loss, net loss, and expense lines.Quarterly reportQ1 2026 Form 10-Q2026-05-13 · Latest quarterly financial statements, revenue recognition, segment disclosure, liquidity, financing, cash flow, and reverse split context.Annual reportFY2025 Form 10-K2026-03-18 · Business description, Nociscan workflow, clinical evidence, scanner compatibility, partner relationships, CPT/reimbursement background, IP, risks, and FY2025 financials.Proxy statement2026 proxy statement2026-04-27 · Annual meeting agenda, shares outstanding, director nominees, executive biographies, board independence, committee structure, auditor, and equity-plan amendment.Current report exhibitJanuary 2026 balance-sheet and milestone release2026-01-13 · Cash balance, zero-debt statement, financing narrative, CLARITY, payer, software, evidence, and MRI-manufacturer milestones.Current reportJanuary 2026 registered-direct offering Form 8-K2026-01-09 · Offering structure, common shares, pre-funded warrants, and securities-purchase agreement context.Current report exhibitMarch 2026 stockholder rights plan release2026-03-19 · Limited-duration rights plan, 10% trigger, rights-eligible warrants, $14.00 right exercise price, and expiration.Current report exhibitApril 2026 stock repurchase release2026-04-22 · Up to $2.5 million repurchase authorization, expected 12-month window, cash funding, and management capital-allocation commentary.